Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients

被引：24

作者：

Nakamura, Yasuhiro ^{[1
,27
]}

Namikawa, Kenjiro ^{[2
]}

Kiniwa, Yukiko ^{[3
]}

Kato, Hiroshi ^{[4
]}

Yamasaki, Osamu ^{[5
]}

Yoshikawa, Shusuke ^{[6
]}

Maekawa, Takeo ^{[7
]}

Matsushita, Shigeto ^{[8
]}

Takenouchi, Tatsuya ^{[9
]}

Inozume, Takashi ^{[10
]}

Nakai, Yasuo ^{[11
]}

Fukushima, Satoshi ^{[12
]}

Saito, Shintaro ^{[13
]}

Otsuka, Atsushi ^{[14
,15
]}

Fujimoto, Noriki ^{[16
]}

Isei, Taiki ^{[17
]}

Baba, Natsuki ^{[18
]}

Matsuya, Taisuke ^{[19
]}

Tanaka, Ryo ^{[20
]}

Kaneko, Takahide ^{[21
]}

Onishi, Masazumi ^{[22
]}

Kuwatsuka, Yutaka ^{[23
]}

Nagase, Kotaro ^{[24
]}

Onuma, Takehiro ^{[25
]}

Nomura, Motoo ^{[26
]}

Umeda, Yoshiyasu ^{[1
,20
]}

Yamazaki, Naoya ^{[2
]}

机构：

[1] Saitama Med Univ, Dept Skin Oncol Dermatol, Int Med Ctr, Saitama, Japan

[2] Natl Canc Ctr, Dept Dermatol Oncol, Tokyo, Japan

[3] Shinshu Univ, Dept Dermatol, Matsumoto, Japan

[4] Nagoya City Univ, Dept Geriatr & Environm Dermatol, Grad Sch Med Sci, Nagoya, Japan

[5] Okayama Univ, Dept Dermatol, Dent & Pharmaceut Sci, Grad Sch Med, Okayama, Japan

[6] Shizuoka Canc Ctr, Dermatol Div, Shizuoka, Japan

[7] Jichi Med Univ, Dept Dermatol, Tochigi, Japan

[8] Natl Hosp Org, Dept Dermato Oncol Dermatol, Kagoshima Med Ctr, Kagoshima, Japan

[9] Niigata Canc Ctr Hosp, Dept Dermatol, Niigata, Japan

[10] Chiba Univ, Dept Dermatol, Chiba, Japan

[11] Mie Univ, Dept Dermatol, Mie, Japan

[12] Kumamoto Univ, Fac Life Sci, Dept Dermatol & Plast Surg, Kumamoto, Japan

[13] Gunma Univ, Dept Dermatol, Grad Sch Med, Maebashi, Japan

[14] Kyoto Univ, Dept Dermatol, Kyoto, Japan

[15] Kindai Univ Hosp, Dept Dermatol, Osaka, Japan

[16] Shiga Univ Med Sci, Dept Dermatol, Otsu, Japan

[17] Osaka Int Canc Inst, Dept Dermatol Oncol, Osaka, Japan

[18] Univ Fukui, Dept Dermatol, Fukui, Japan

[19] Asahikawa Med Univ, Dept Dermatol, Asahikawa, Japan

[20] Kawasaki Med Sch, Dept Dermatol, Kurashiki, Japan

[21] Juntendo Univ, Dept Dermatol, Urayasu Hosp, Chiba, Japan

[22] Iwate Med Univ, Dept Dermatol, Iwate, Japan

[23] Nagasaki Univ, Dept Dermatol, Nagasaki, Japan

[24] Saga Univ, Fac Med, Dept Internal Med, Div Dermatol, Saga, Japan

[25] Univ Yamanashi, Dept Dermatol, Yamanashi, Japan

[26] Kyoto Univ, Dept Clin Oncol, Kyoto, Japan

[27] Saitama Med Univ, Dept Skin Oncol Dermatol, Int Med Ctr, 1397-1 Yamane, Saitama 3501298, Japan

来源：

EUROPEAN JOURNAL OF CANCER | 2022年 / 176卷

关键词：

CTLA-4; antigen; Immunotherapy; Ipilimumab; Melanoma; Nivolumab; Pembrolizumab; Programmed cell death 1 receptor; Retrospective studies; Japan; SINGLE-ARM; OPEN-LABEL; PD-1; BLOCKADE; PHASE-II; MUCOSAL; IPILIMUMAB; INHIBITORS; NIVOLUMAB; MUTATION; SAFETY;

D O I：

10.1016/j.ejca.2022.08.030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Although anti-PD-1 antibody monotherapy (PD-1) is commonly used to treat advanced acral melanoma (AM), its efficacy is limited. Further, data on the efficacy of PD-1 plus anti-CTLA-4 antibody (PD-1+CTLA-4) for the treatment of AM are limited. Therefore, we compared the efficacy of PD-1+CTLA-4 and PD-1 in the treatment of Japanese patients with advanced AM. Methods: This retrospective study evaluated patients with advanced AM who were treated with PD-1 or PD-1+CTLA-4 as first-line immunotherapy in 24 Japanese institutions between 2014 and 2020. Treatment efficacy focussing on the objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) was compared between the two groups. Results: In total, 254 patients (palm and sole melanoma [PSM], n = 180; nail apparatus melanoma [NAM], n = 74) were included. Among the patients with PSM, the ORR (19% vs. 31%; P = 0.44), PFS (5.9 vs. 3.2 months; P = 0.74), and OS (23.1 vs. not reached; P = 0.55) did not differ significantly between the PD-1 and PD-1+CTLA-4 groups. Among the patients with NAM, the ORR (61% vs. 10%; P < 0.001) was significantly higher and PFS was longer (6.4 vs. 3.8 months; P = 0.10) in the PD-1+CTLA-4 group than in the PD-1 group. Cox multivariate analysis demonstrated that PD-1+CTLA-4 is an independent predictor of a favourable PFS in patients with NAM (P = 0.002). Conclusions: The efficacy of PD-1+CTLA-4 is not superior to that of PD-1 for the treatment of advanced PSM. However, PD-1+CTLA-4 may be more efficacious than PD-1 for the treatment of advanced NAM. (C) 2022 Elsevier Ltd. All rights reserved.

引用

页码：78 / 87

页数：10

共 50 条

[41] Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’’
Samantha Bowyer
Prashanth Prithviraj
Paul Lorigan
James Larkin
Grant McArthur
Victoria Atkinson
Michael Millward
Muoi Khou
Stefan Diem
Sangeetha Ramanujam
Ben Kong
Elizabeth Liniker
Alexander Guminski
Phillip Parente
Miles C Andrews
Sagun Parakh
Jonathan Cebon
Georgina V Long
Matteo S Carlino
Oliver Klein
British Journal of Cancer, 2017, 116 : e15 - e15
[42] Anti-PD-1 therapies—a new first-line option in advanced melanoma
Ryan J. Sullivan
Keith T. Flaherty
Nature Reviews Clinical Oncology, 2015, 12 : 625 - 626
[43] Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy.
Gide, Tuba Nur
Quek, Camelia
Madore, Jason
Menzies, Alexander M.
Dent, Rebecca
Carlino, Matteo S.
Guminski, Alex
Saw, Robyn
Thompson, John F.
Wilmott, James S.
Scolyer, Richard A.
Long, Georgina V.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
[44] Real-world efficacy of anti-PD-1 antibodies in advanced acral melanoma patients: A retrospective, multicenter study (JAMP study).
Nakamura, Yasuhiro
Namikawa, Kenjiro
Yoshino, Koji
Yoshikawa, Shusuke
Uchi, Hiroshi
Goto, Katsunobu
Nakamura, Yoshiyuki
Fukushima, Satoshi
Kiniwa, Yukiko
Takenouchi, Tatsuya
Uhara, Hisashi
Kawai, Toru
Hatta, Naohito
Funakoshi, Takeru
Teramoto, Yukiko
Otsuka, Atsushi
Doi, Haruki
Ogata, Dai
Matsushita, Shigeto
Yamazaki, Naoya
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[45] Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations
Seidel, Judith A.
Otsuka, Atsushi
Kabashima, Kenji
FRONTIERS IN ONCOLOGY, 2018, 8
[46] Prognostic factors for survival in patients with metastatic skin melanoma, receiving first- line treatment with anti-PD-1 or anti-PD-1 and anti-CTLA-4 immunotherapy regimen at the Instituto Nacional de Cancerolog?a (Bogot?, Colombia)
Marcela Zuluaga-Liberato, Andrea
Eduardo Bonilla-Gonzalez, Carlos
Contreras-Mejia, Fernando
Alexander Carreno-Duenas, Jose
REVISTA COLOMBIANA DE CANCEROLOGIA, 2023, 27 (01): : 91 - 102
[47] A retrospective multicenter study on the efficacy and safety of disitamab vedotin monotherapy versus combination with anti-PD-1 immunotherapy in advanced gastric cancer
Dong, Shuailei
Wei, Chen
Wang, Xueting
Yang, Xinyi
Shen, Wei
Li, Shuyi
Xu, Jiye
Ma, Yijie
Bie, Liangyu
Yu, Wenyue
Li, Ning
SCIENTIFIC REPORTS, 2025, 15 (01):
[48] Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma
Zhu, Meiyan
Jin, Meng
Zhao, Xiao
Shen, Shunli
Chen, Yihan
Xiao, Han
Wei, Guangyan
He, Qiang
Li, Bin
Peng, Zhenwei
BMC MEDICINE, 2024, 22 (01)
[49] First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland
Cybulska-Stopa, Bozena
Pacholczak-Madej, Renata
Kaminska-Winciorek, Grazyna
Zietek, Marcin
Czarnecka, Anna M.
Piejko, Karolina
Galus, Lukasz
Ziolkowska, Barbara
Kieszko, Stanislaw
Kempa-Kaminska, Natasza
Calik, Jacek
Rolski, Janusz
Salek-Zan, Agata
Gajewska-Wicher, Katarzyna
Drosik-Kwasniewska, Anna
Rogala, Pawel
Kubiatowski, Tomasz
Suwinski, Rafal
Mackiewicz, Jacek
Rutkowski, Piotr
IMMUNOTHERAPY, 2021, 13 (04) : 297 - U32
[50] Efficacy of anti-CTLA-4 after progression on anti-PD1 therapy in advanced melanoma
Aya Moreno, F.
Fernandez-Martinez, A.
Gaba, L.
Victoria, I.
Arance Fernandez, A. M.
ANNALS OF ONCOLOGY, 2015, 26 : 6 - 6

← 1 2 3 4 5 →